Nephrology Dialysis Transplantation, Vol 12, Issue 12 2569-2575, Copyright © 1997 by Oxford University Press
L Firmat, S Briancon, D Hestin, B Aymard, E Renoult, T Huu, M Kessler and L des Nephrologues de l'Est
Background: As yet, no clinical or morphological
prognostic classification of IgA nephropathy (IgAN) has been generally
accepted. The objective our study was to quantify the risk of developing
end-stage renal failure (ESRF) in IgAN. Methods: We
report a prospective longitudinal study of 210 patients with IgAN confirmed
by biopsy between 1987 and 1991. Thirty-two (15.2%) patients were lost to
follow-up. Mean follow-up after renal biopsy was 5.6 (SD=2.6) years. The
variables included age, gender, illnesses prior to discovery of IgAN,
clinical features at IgAN discovery, 24-h proteinuria, serum creatinine,
IgA level, and antihypertensive drugs taken at the time of renal biopsy.
Sixty-six renal biopsies were classified by light-microscopy according to
Lee's morphological classification. The end-point was ESRF. Survival was
analysed by a backward and forward stepwise procedure using the Cox model.
The most accurate determination of relative risk was obtained by assessing
collinearity of the variables. Results: Thirty-three
patients (15.7%) (31 men) developed ESRF. The five univariately significant
variables: gender, gross haematuria, 24-h proteinuria (24-P), serum
creatinine (SC), and antihypertensive treatment, were candidates for
multivariate analysis. The final model used SC (⩽100, 100-150
>150 &mgr;mol/l), 24-P (<1, ⩾1 g/day) and gender
(female vs male) as independent variables (relative
risk and 95% confidence interval were 3.5 (2.1, 5.9 for SC; 5.1 (1.9, 13.6)
for 24-P; and 3.5 (0.9, 15) for gender). These estimates were used to
construct a prognostic classification of ESRF for men with IgAN: stage 1
(SC⩽150 &mgr;mol/l and 24-P<1 g/day), stage 2
((SC>150 &mgr;mol/l and 24-P<1 g/day) or (SC⩽150
&mgr;mol/l and 24-P⩾1 g/day)); stage 3 (SC>150
&mgr;mol/l and 24-P⩾1 g/day). The ESRF-free survival was
estimated with Kaplan-Meier analysis. It was 98.5% for stage 1, 86.6% for
stage 2, 21.3% for stage 3 (P<0.001), 6 years after histological
diagnosis. The validity of Lee's prognostic classification was confirmed
using an independent sample. Conclusions: These
classifications identify groups at high risk of ESRF. Therapeutic studies
should focus on these groups. Key words: end-stage
renal failure; IgA nephropathy; prognostic classification
ORIGINAL ARTICLES
IgA nephropathy: prognostic classification of end-stage renal failure
Service de Nephrologie, Hopitaux de Brabois, F-54500 Vandoeuvre-les-Nancy, France; Corresponding author
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. C. Cattran, H. N. Reich, H. J. Beanlands, J. A. Miller, J. W. Scholey, S. Troyanov, and for the Genes, Gender and Glomerulonephritis Group The impact of sex in primary glomerulonephritis Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2247 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Reich, S. Troyanov, J. W. Scholey, D. C. Cattran, and for the Toronto Glomerulonephritis Registry Remission of Proteinuria Improves Prognosis in IgA Nephropathy J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3177 - 3183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Brown, H. R. Lock, T. G.A.M. Wolfs, W. A. Buurman, S. H. Sacks, and M. G. Robson Toll-Like Receptor 4 Ligation on Intrinsic Renal Cells Contributes to the Induction of Antibody-Mediated Glomerulonephritis via CXCL1 and CXCL2 J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1732 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wakai, T. Kawamura, M. Endoh, M. Kojima, Y. Tomino, A. Tamakoshi, Y. Ohno, Y. Inaba, and H. Sakai A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2800 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Brown, H. R. Lock, S. H. Sacks, and M. G. Robson TLR2 Stimulation of Intrinsic Renal Cells in the Induction of Immune-Mediated Glomerulonephritis J. Immunol., August 1, 2006; 177(3): 1925 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Brown, S. H. Sacks, and M. G. Robson Toll-Like Receptor 2 Agonists Exacerbate Accelerated Nephrotoxic Nephritis J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1931 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Vikse, L. Bostad, K. Aasarod, D. E. Lysebo, and B. M. Iversen Prognostic factors in mesangioproliferative glomerulonephritis Nephrol. Dial. Transplant., September 1, 2002; 17(9): 1603 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. FLOEGE and J. FEEHALLY IgA Nephropathy: Recent Developments J. Am. Soc. Nephrol., December 1, 2000; 11(12): 2395 - 2403. [Full Text]
|
|
|
|
|
|
L. FRIMAT, C. PHILIPPE, M.-N. MAGHAKIAN, P. JONVEAUX, B. H. DE LIGNY, F. GUILLEMIN, and M. KESSLER Polymorphism of Angiotensin Converting Enzyme, Angiotensinogen, and Angiotensin II Type 1 Receptor Genes and End-Stage Renal Failure in IgA Nephropathy: IGARAS--A Study of 274 Men J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2062 - 2067. [Abstract] [Full Text]
|
|
|
|
|
|
K. Oka, E. Imai, T. Moriyama, Y. Akagi, A. Ando, M. Hori, A. Okuyama, K. Toki, M. Kyo, Y. Kokado, et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor Nephrol. Dial. Transplant., May 1, 2000; 15(5): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. NEUGARTEN, A. ACHARYA, and S. R. SILBIGER Effect of Gender on the Progression of Nondiabetic Renal Disease: AMeta-Analysis J. Am. Soc. Nephrol., February 1, 2000; 11(2): 319 - 329. [Abstract] [Full Text] [PDF]
|
|